title: Effect of antiandrogen treatment on bone density and bone geometry in adolescents with polycystic ovary syndrome.
abstract: OBJECTIVE
  To determine the impact of antiandrogen treatment on bone density and geometry.
  
  
  METHODS
  Prospective cohort investigation.
  
  
  METHODS
  Academic research institute.
  
  
  METHODS
  38 (age 14.96 ± 1.42 yr) subjects with PCOS.
  
  
  METHODS
  Treated with metformin (n = 17) or metformin and antiandrogen (n = 21).
  
  
  METHODS
  Bone density and geometry parameters at baseline and after a mean duration of 1.92 ± 0.88 years using peripheral quantitative computed tomography of the forearm.
  
  
  RESULTS
  At baseline, z-scores for trabecular (0.53 ± 1.02) and cortical BMD (0.79 ± 1.55) as well as total (0.62 ± 1.07) and medullary cross sectional area (CSA) (0.79 ± 1.29) were elevated. Cortical CSA (-0.01 ± 1.10) and bone strength strain index (SSI) z-scores (-0.01 ± 1.10) were normal. Muscle CSA z-score (0.12 ± 1.70) was normal, but grip strength (-1.60 ± 1.15) was significantly reduced. There were no significant changes within and between the two treatment options in respect to bone density and bone geometry parameters. With antiandrogen treatment, free androgen index (FAI) was significantly lower and grip strength further decreased (P < .001).
  
  
  CONCLUSIONS
  No significant changes in bone mineral density and geometry parameters took place in PCOS women irrespective of treatment followed over a time of almost two years. General muscle weakness expressed as low grip strength may influence further bone development in PCOS.
authors.affiliation: Division of Pediatric Endocrinology, University Children's Hospital, Ludwig-Maximilian University, Munich, Germany. Susanne.Bechtold@med.uni-muenchen.de
authors.forename: Susanne
authors.initials: S
authors.lastname: Bechtold
authors.forename: Robert
authors.initials: R
authors.lastname: Dalla Pozza
authors.forename: Stephanie
authors.initials: S
authors.lastname: Putzker
authors.forename: Julia
authors.initials: J
authors.lastname: Roeb
authors.forename: Matthias
authors.initials: M
authors.lastname: Buckel
authors.forename: Claudia
authors.initials: C
authors.lastname: Weissenbacher
authors.forename: Heinrich
authors.initials: H
authors.lastname: Schmidt
mesh_terms: D000293:Adolescent; D000726:Androgen Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects*; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005542:Forearm / Q000000981:diagnostic imaging; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D008687:Metformin / Q000494:pharmacology / Q000627:therapeutic use*; D053580:Muscle Strength / Q000187:drug effects; D018482:Muscle, Skeletal / Q000033:anatomy & histology / Q000000981:diagnostic imaging / Q000187:drug effects; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy*; D011884:Radius / Q000033:anatomy & histology / Q000000981:diagnostic imaging / Q000187:drug effects; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D007004:Hypoglycemic Agents; D008687:Metformin